Tempus launches ArteraAI prostate test for metastatic patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use
May 21, 2026 8:30 AM EDTCHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic test will be fully integrated into the Tempus platform, providing urologists and oncologists with a digital pathology solution that helps inform personalization of therapy intensity in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patients clinical information and histopathology biopsy image to... More
